GLP-1 Research: Incretin Therapies & Blood Pressure

A large-scale systematic review and meta-analysis published in the European Journal of Preventive Cardiology in May 2026 suggests that incretin-based therapies — including GLP-1 receptor agonists and newer dual and triple receptor agonists — may offer meaningful cardiovascular benefits beyond weight loss alone, including modest but clinically relevant reductions in blood pressure and an 18% lower risk of all-cause mortality. For the millions of adults living with both obesity and hypertension, these findings could have significant implications for how clinicians approach integrated cardiometabolic care.

What This Study Found

Researchers conducted a comprehensive search of PubMed, EMBASE, and ClinicalTrials.gov, ultimately identifying 85 randomized controlled trials (RCTs) encompassing 90,977 participants with a median follow-up of eight months. The analysis evaluated the effects of incretin-based therapies — specifically GLP-1 receptor agonists (GLP-1-RAs), dual GIP/GLP-1 receptor agonists, and triple glucagon/GIP/GLP-1 receptor agonists — on office systolic blood pressure (SBP), diastolic blood pressure (DBP), all-cause mortality, hypoglycemia, and pancreatitis (Basile et al., 2026).

The study's primary findings were as follows:

• GLP-1 receptor agonists reduced SBP by an average of 3.4 mmHg (95% CI: 2.8–4.0) and DBP by 0.9 mmHg (95% CI: 0.5–1.2).
• Dual receptor agonists (GIP/GLP-1) produced more pronounced reductions, with SBP falling by 5.1 mmHg and DBP by 1.8 mmHg.
• Triple receptor agonists (glucagon/GIP/GLP-1) were associated with the greatest reductions: SBP down 6.6 mmHg and DBP down 2.1 mmHg.
• All-cause mortality was reduced by 18% (RR 0.82, 95% CI: 0.76–0.90) among those receiving incretin-based therapy compared to placebo.
• Critically, incretin-based therapy did not significantly increase the risk of hypoglycemia (RR 1.05, 95% CI: 0.83–1.33) or pancreatitis (RR 0.84, 95% CI: 0.61–1.15).

One of the study's more nuanced findings was the significant association between the degree of weight loss and the magnitude of blood pressure reduction. Researchers found that every kilogram lost was associated with a progressively greater decrease in both systolic and diastolic blood pressure, suggesting that the antihypertensive effects of these therapies are at least partially mediated through weight reduction. However, the authors also noted the need for long-term RCTs to clarify weight-independent mechanisms that may be driving blood pressure improvements.

Clinical Significance

Hypertension and obesity are two of the most prevalent and intertwined drivers of cardiovascular disease worldwide. The authors note that these conditions frequently coexist and synergistically increase cardiovascular risk — making therapies that address both simultaneously particularly valuable from a clinical standpoint.

While a 3–6 mmHg reduction in systolic blood pressure may appear modest in isolation, researchers emphasize its potential population-level importance. Epidemiological data consistently suggests that even small, sustained reductions in SBP are associated with meaningful decreases in stroke, myocardial infarction, and cardiovascular mortality at scale. When combined with the 18% reduction in all-cause mortality observed in this meta-analysis, the cardiovascular benefit profile of incretin-based therapies — particularly newer dual and triple agonists — appears increasingly compelling.

The study also highlights that the safety profile remained favorable across the pooled trial data. The absence of a significant increase in hypoglycemia is particularly noteworthy, as this is often a limiting factor in the intensification of glucose-lowering or weight-management therapies. The researchers suggest these findings support the use of incretin-based therapies as part of an integrated, multidisciplinary approach to managing both obesity and hypertension.

The progression from single GLP-1 receptor agonism to dual and triple receptor agonism appears to follow a meaningful dose-response pattern for blood pressure reduction, with triple agonists demonstrating nearly double the antihypertensive effect of GLP-1 receptor agonists alone. The authors describe dual and triple agonists as showing particular promise in this context, though they acknowledge the evidence base for these newer agents is still maturing.

Current Access and Compliance Context

Despite the growing body of evidence supporting incretin-based therapies for cardiometabolic health, access remains a significant challenge for many patients. Supply constraints, high out-of-pocket costs, and inconsistent insurance coverage have all been reported as barriers to consistent use of GLP-1 receptor agonists and their newer analogs in clinical practice.

Patient persistence and adherence are also important considerations. Long-term metabolic benefits — including the sustained blood pressure reductions suggested by this research — are likely dependent on continuous use, which underscores the importance of individualized care plans developed in partnership with qualified healthcare providers. Abrupt discontinuation has been associated with weight regain in prior studies, and it is reasonable to anticipate that associated blood pressure benefits may also diminish without sustained therapy.

Patients considering incretin-based therapies should work with physicians experienced in metabolic and cardiovascular medicine who can evaluate candidacy, monitor response, and integrate these agents into a broader lifestyle and risk-reduction strategy. The study's authors specifically call for a multidisciplinary approach, recognizing that pharmacotherapy alone is rarely sufficient for long-term cardiometabolic health optimization.

What Patients Should Know

If you are living with overweight or obesity and have been diagnosed with hypertension or elevated cardiovascular risk, this research suggests that incretin-based therapies may offer benefits that extend well beyond the scale. The study findings indicate that these medications may help lower blood pressure and reduce mortality risk — but they are not a standalone solution and are not appropriate for everyone.

Here are key takeaways to discuss with your healthcare provider:

• Blood pressure benefits appear to scale with weight loss. The more weight lost, the greater the expected reduction in both systolic and diastolic blood pressure, according to this analysis.
• Newer dual and triple agonists may offer greater antihypertensive effects than older GLP-1 receptor agonists alone, though access and long-term data are still evolving.
• The safety profile in this large pooled analysis was favorable, with no significant increase in hypoglycemia or pancreatitis — two commonly cited safety concerns.
• These are prescription medications requiring individualized medical evaluation, monitoring, and ongoing support. Self-administration without physician guidance is not appropriate.
• Long-term data are still needed. The researchers themselves call for additional RCTs to clarify the durability of blood pressure effects and any weight-independent mechanisms at play.

It is also worth noting that while this meta-analysis pooled data from over 90,000 participants, the median follow-up was only eight months. Longer-term studies will be essential to fully characterize the sustained cardiovascular benefits and safety profile of these therapies, particularly for the newer multi-receptor agonists.

Conclusion

The systematic review and meta-analysis by Basile and colleagues represents one of the most comprehensive evaluations to date of incretin-based therapies and their effects on blood pressure in adults with overweight or obesity. The study suggests these medications — particularly dual and triple receptor agonists — may offer a meaningful, safe, and synergistic approach to managing two of the most prevalent cardiovascular risk factors simultaneously.

As the evidence base for these therapies continues to grow, access to qualified medical guidance has never been more important. If you are interested in learning whether incretin-based therapy may be appropriate for your cardiometabolic health goals, we encourage you to consult with a knowledgeable physician who can provide personalized, evidence-informed care.

Find a qualified provider near you at peptideassociation.org/find-a-doctor.

---

Medical Disclaimer: This article is intended for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. The information presented is based on published peer-reviewed research and should not be used as a substitute for professional medical consultation. Always consult a qualified healthcare provider before starting, stopping, or modifying any medication or treatment plan. Individual results may vary.

---

Citation: Basile C, Merolla A, Mancusi C, et al. Effect of incretin-based therapies on blood pressure: a systematic review and meta-analysis. European Journal of Preventive Cardiology. 2026;zwaf560. doi:10.1093/eurjpc/zwaf560. PMID: 40899050.